IntegraGen snags $2.4M to market autism Dx

Cambridge, MA-based IntegraGen pulled in $2.4 million in financing, earmarking the cash to commercialize its autism diagnostics and fund the development of its pipeline cancer tests.

The private fundraising affirms the company's status a promising producer of molecular diagnostics, IntegraGen's CEO said in a statement, especially considering the tepid venture capital climate around the industry. "This is a testimonial to investors' confidence in IntegraGen's efforts, specifically those associated with the commercialization of a genetic autism screening test this year in the U.S., as well as our progress in the field of oncology biomarkers," Bernard Courtieu said.

Back in April, IntegraGen launched Arisk Test, a gender-specific assay of genetic markers that indicate autism. The latest financing will help the company expand the test's market reach, IntegraGen said, and contribute to its R&D efforts. In the pipeline are genetic tests for colorectal and liver cancers, and the company is also working on further autism diagnostics.

The company, owned by France-based IntegraGen SA, reported revenues of $5.6 million last year.

- read the company's release
- get more from Mass High Tech

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.